2024-09-27 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance Comparison:**

* **Cumulative Return:** REGN: 96.72%, VOO: 133.29%
* **Relative to VOO:** REGN is lagging behind by -36.57% in terms of cumulative returns. The current relative divergence stands at 38.34%, indicating that REGN is performing at the 38.34th percentile relative to its historical performance range compared to VOO.

**2. Recent Price Movement:**

* **Closing Price:** $1031.15
* **Moving Averages:**
    * 5-day: $1091.43
    * 20-day: $1141.1
    * 60-day: $1116.97

REGN's price is currently below all three moving averages, suggesting a potential downtrend in the short term.

**3. Technical Indicators:**

* **RSI:** 26.19 (below 30, indicating oversold conditions)
* **PPO:** -1.4 (negative, suggesting potential weakness)
* **Delta_Previous_Relative_Divergence:** -28.35 (negative, indicating short-term bearish momentum)
* **Expected_Return:** 0.0% (maximum expected return over the next 5 years, based on current investment)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings (2024-08-01) beat analysts' expectations for both EPS and revenue, showing strong growth.  The company's consistent earnings performance and growth in revenue suggest a positive outlook for the future.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Regeneron's stock price has been under pressure recently due to concerns about competition in the eye disease treatment market and the potential for lower-than-expected growth in its key drug Eylea.
* **Analyst Opinions:** Some analysts have expressed concerns about Regeneron's long-term growth prospects due to the increasing competition in its core markets. However, others remain optimistic about the company's strong pipeline and its ability to continue developing innovative treatments.
* **Performance Highlights:** Regeneron has shown significant success in developing treatments for various diseases, including eye diseases, cancer, and inflammatory disorders. 

**6. Overall Analysis:**

REGN has a strong track record of earnings performance and a robust pipeline of potential new treatments.  However, the stock is currently lagging behind the broader market due to concerns about competition and growth prospects.  While technical indicators suggest potential weakness, the company's recent earnings beat indicates a strong underlying business. 

**7. Conclusion:**

Overall, Regeneron Pharmaceuticals Inc. (REGN) remains a valuable company with a solid business model and a promising future. Investors may want to closely monitor the company's upcoming earnings releases and its progress in developing new treatments to assess its future performance potential. Despite recent price weakness, the company's positive fundamentals suggest that it may be a good long-term investment opportunity. 
